This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Jelle Wesseling group


Jelle Wesseling


Personal details


Jelle Wesseling is consultant breast pathologist. He became Master of Science (MSc) in Medicine in 1987 and cum laude MSc in chemistry focusing on molecular and cell biology in 1991, both at the University of Groningen, the Netherlands. He received his PhD at the Netherlands Cancer Institute in 1997 under supervision of Prof. Dr. Piet Borst, Prof. Dr. Carl Figdor, and Dr. John Hilkens about the role of the carcinoma-associated mucin episialin (MUC1, CD227, EMA, CA15-3 antigen) in cell adhesion and tumor progression. He obtained his MD cum laude at the Free University in Amsterdam in 1999. He was trained as a pathologist at the University Medical Center Groningen for which he was registered in 2004. He returned to the NKI in 2006 where he became a consultant breast pathologist and group leader. He is member of various breast cancer working committees, both in the Netherlands as well as in Europe.
His research focuses on optimizing personalized diagnosis and treatment of each breast cancer patient by searching for novel prognostic and predictive biomarkers using a combination of pathology, molecular analyses, and epidemiology. Ultimately, he aims at answering the questions which breast cancer patient needs what type of treatment for how much benefit.

Share this page